Secondary Prevention of Atrial Fibrillation (Impact of Renin-Angiotensin-Aldosterone System Inhibition)
Status:
Terminated
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
In the present application, we propose to refine and extend current insight into AAF
mechanism and therapy by examining the importance of pharmacologic RAAS inhibition, ACE
genotype, and their interaction in secondary AF prevention. We have 3 specific aims:
1. To confirm that RAAS inhibition therapy reduces the incidence of AF recurrence.
2. To test the hypothesis that the incidence of AF recurrence in the absence of RAAS
inhibition therapy is higher among patients with the D allele.
3. To explore the hypothesis that RAAS inhibition therapy is more effective for preventing
AF recurrence in patients with the DD genotype than in those with DI or II genotypes.